drugset
drugset / Trial / NCT06755450

Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

NCT06755450 ↗

Phase 1 Recruiting 40 enrolled Aurigene Discovery Technologies Limited
NaSequentialOpen-labelTreatment

Summary

A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)

Timeline

Start
2025-01-15
Primary completion
2027-01-15
Completion
2028-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AUR112 Unknown 100 mg Oral
Subject AUR112 Unknown 200 mg Oral
Subject AUR112 Unknown 400 mg Oral
Subject AUR112 Unknown 600 mg Oral
Subject AUR112 Unknown 900 mg Oral
Subject AUR112 Unknown 1200 mg Oral

Indications

No indication recorded.